^
Association details:
| Biomarker: | TROP2 overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Trodelvy (sacituzumab govitecan-hziy) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
Excerpt:
...Sacituzumab govitecan (SG)...Trop-2 expression by IHC was detected in 95.1% of USC samples (99/104). Primary tumor cell-lines overexpressing Trop-2 were significantly more sensitive to SG when compared to control ADC ( p < 0.05). SG is remarkably active against...Uterine serous carcinoma (USC)...overexpressing Trop-2 in vitro and in vivo.
DOI:
10.1016/j.ygyno.2019.11.018
